NASDAQ: PHVSPharvaris Nv Stock
$18.50-2.37 (-11.36%)
Updated Oct 2, 2023
PHVS Price
$18.50
Fair Value Price
N/A
Market Cap
$755.22M
52 Week Low
$1.77
52 Week High
$26.86
P/E
-6.08x
P/B
3.87x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$101.33M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$89M
Beta
0.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PHVS Overview
Pharvaris N.V. is developing therapies for rare diseases. Its pipeline includes PHA121, PHVS416, PHVS719, all to treat hereditary angioedema. Pharvaris N.V was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHVS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHVS is good value based on its book value relative to its share price (3.87x), compared to the US Biotechnology industry average (5.05x)
P/B vs Industry Valuation
PHVS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHVS due diligence checks available for Premium users.
Be the first to know about important PHVS news, forecast changes, insider trades & much more!
PHVS News
Valuation
PHVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.08x
Industry
14.19x
Market
12.38x
PHVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.87x
Industry
5.05x
PHVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHVS's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.1M
Profit Margin
0%
PHVS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$208.5M
Liabilities
$17.6M
Debt to equity
0.09
PHVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.5M
Investing
-$38.5k
Financing
$70.2M
PHVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHVS vs Biotech Stocks
Pharvaris Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.